- Stocks
- Pharma & Healthcare
- Anuh Pharma
Anuh Pharma share price
NSE: ANUHPHRPharma & HealthcareDrug Manufacturers - Specialty & Generic
Anuh Pharma at a glance
Anuh Pharma (NSE: ANUHPHR) closed at ₹80.29 on 22 Oct 2026, up 0.68% on the day. With a market capitalisation of ₹805 Cr, it ranks 1562nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 19.6× trailing earnings, against a return on equity of 14.5% in FY25. Over the past year the share price has risen 0.4%. Its 52-week range is ₹67.00 (30 Mar 2026) to ₹99.50 (8 Sep 2026); the last close is 19.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹202 Cr (+2.0% year on year) and net profit ₹12 Cr (−6.3%), on a standalone basis. Promoters held 71.80% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹805 CrRank 1562 on NSE
- P/E (trailing)
- 19.6×
- Price to book
- 2.29×FY25
- EPS (TTM)
- ₹4.93to Q4 FY26
- ROE
- 14.5%FY25
- ROCE
- 18.8%FY25
- Debt to equity
- 0.03FY25
- Net profit margin
- 7.2%FY25
- Book value / share
- ₹65.06FY25
- Dividend payout
- 26.5%FY25
- 52-week high
- ₹99.508 Sep 2026
- 52-week low
- ₹67.0030 Mar 2026
- 1-year return
- +0.4%
- RSI (14-day)
- 41.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.68% | −7.7% | −15.4% | +0.5% | +0.4% |
Anuh Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹138 Cr | ₹166 Cr | ₹160 Cr | ₹198 Cr | ₹186 Cr | ₹186 Cr | ₹197 Cr | ₹202 Cr |
| Revenue YoY | −14.6% | +11.0% | −7.3% | +20.9% | +35.2% | +12.0% | +23.6% | +2.0% |
| Net profit | ₹10 Cr | ₹15 Cr | ₹10 Cr | ₹12 Cr | ₹8 Cr | ₹8 Cr | ₹13 Cr | ₹12 Cr |
| Net profit YoY | −19.1% | +8.7% | −45.9% | −18.9% | −12.7% | −49.4% | +30.1% | −6.3% |
| Net margin | 6.9% | 9.1% | 6.5% | 6.3% | 4.5% | 4.1% | 6.8% | 5.8% |
| EPS | ₹1.90 | ₹3.00 | ₹2.06 | ₹2.49 | ₹1.66 | ₹0.76 | ₹1.34 | ₹1.17 |
Anuh Pharma financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹307 Cr | ₹432 Cr | ₹487 Cr | ₹527 Cr | ₹647 Cr | ₹662 Cr |
| Operating profit | ₹19 Cr | ₹39 Cr | ₹39 Cr | ₹47 Cr | ₹78 Cr | ₹61 Cr |
| Net profit | ₹14 Cr | ₹28 Cr | ₹31 Cr | ₹36 Cr | ₹60 Cr | ₹47 Cr |
| EPS (₹) | ₹5.71 | ₹5.67 | ₹6.10 | ₹7.22 | ₹11.98 | ₹9.45 |
| Cash from operations | ₹49 Cr | −₹19 Cr | ₹29 Cr | ₹54 Cr | ₹13 Cr | ₹37 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹162 Cr | ₹191 Cr | ₹214 Cr | ₹241 Cr | ₹291 Cr | ₹326 Cr |
Anuh Pharma shareholding pattern
| Holder | 30 Jun 2025 | 16 Jul 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.92% | 69.92% | 71.82% | 71.82% | 71.80% | 71.80% |
| Foreign institutions | 0.04% | 0.03% | 0.00% | 0.00% | 0.05% | 0.01% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 30.04% | 30.06% | 28.18% | 28.18% | 28.16% | 28.19% |
Anuh Pharma vs peers
The listed Pharma & Healthcare companies nearest to Anuh Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| THEMISMEDThemis Medicare | ₹98.08 | +3.13% | −22.8% | ₹903 Cr | — | — |
| SGRLShree Ganesh Re | ₹658.25 | +3.32% | — | ₹845 Cr | 47.7 | — |
| ANUHPHRAnuh Pharma | ₹80.29 | +0.68% | +0.4% | ₹805 Cr | 19.6 | — |
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
Ask anything about Anuh Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against ANUHPHR's own history. Try: “Why has ANUHPHR moved over the last three months?” · “Backtest a 50-day moving-average crossover on ANUHPHR over five years” · “Compare ANUHPHR with THEMISMED on margins and valuation”
Frequently asked questions about Anuh Pharma
What is the share price of Anuh Pharma today?
Anuh Pharma (NSE: ANUHPHR) last closed at ₹80.29 on 22 Oct 2026. Its 52-week high is ₹99.50 and its 52-week low is ₹67.00.
What is the market cap of Anuh Pharma?
Anuh Pharma's market capitalisation is ₹805 Cr (₹805 Cr) at the 22 Oct 2026 close, ranking 1562nd among the NSE companies Pivot tracks.
What is the P/E ratio of Anuh Pharma?
Anuh Pharma trades at a trailing P/E of 19.6. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 47.7.
What is the ROE and ROCE of Anuh Pharma?
Return on equity was 14.5% in FY25 and return on capital employed was 18.8% in FY25 (standalone figures).
Is Anuh Pharma a debt-free company?
Anuh Pharma is close to debt-free: its debt-to-equity ratio was 0.03 in FY25.
What were Anuh Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Anuh Pharma reported revenue of ₹202 Cr, +2.0% year on year, and net profit of ₹12 Cr, −6.3% year on year.
How has Anuh Pharma stock performed over the last year?
Anuh Pharma's share price has risen 0.4% over the past year, +0.5% over three months and −15.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Anuh Pharma?
As of 30 Jun 2026: promoters 71.80%, foreign institutions 0.01%, domestic institutions 0.00%, non-institutions 28.19%.
Who are Anuh Pharma's competitors?
The listed Pharma & Healthcare companies closest to Anuh Pharma by market cap are Themis Medicare, Shree Ganesh Re, Kilitch Drugs (India), Vikram Thermo, Zim Laboratories and Valiant Laboratories.
Is Anuh Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Anuh Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ANUHPHR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text